Indoco Remedies Q2 FY27 Revenue Crosses ₹500 Crore

Quarterly revenue reaches a new milestone

Indoco Remedies reported consolidated revenue of ₹506.9 crore for the second quarter of FY27, up 7.4% year-on-year from ₹471.8 crore. The result marked the first time the company crossed ₹500 crore in quarterly consolidated revenue. Management discussed the performance during its earnings call held on October 27, 2026. The reported revenue was marginally above the ₹504 crore forecast referenced in the call material. The company described the quarter as a period of progress across key business segments despite a difficult operating environment. However, growth was uneven across the portfolio, with domestic formulations recording a year-on-year decline. The earnings update therefore reflected both a revenue milestone and continuing pressure on costs and selected domestic brands.

Domestic formulations decline during the quarter

Domestic formulations revenue stood at ₹212.8 crore in Q2 FY27, compared with ₹226.1 crore in the corresponding quarter a year earlier. This represented a 5.9% year-on-year decline. Management attributed the weakness partly to an absent monsoon, which affected demand conditions. It also cited degrowth in key brands including Fabrix Plus and OxyPod. The domestic business remains a major part of the company’s operating profile, making the decline relevant to the overall quarter. Management said it expects sales to become more predictable in the second half of FY27. It retained its high single-digit domestic growth guidance for the full financial year.

Some therapy areas show strong growth

The domestic portfolio did show strength in selected therapeutic segments. Gastrointestinal products grew 30.3% during the period, according to the call highlights. The stomatological portfolio grew 34.8%. Cyclopam, identified as a flagship brand, crossed ₹200 crore in sales. These gains indicate that performance varied substantially between brands and therapy categories. The growth in these portfolios partly offset pressure in other domestic products. But the reported domestic formulations revenue still declined at the aggregate level. The company did not provide a broader therapy-wise revenue split in the supplied material.

Costs keep EBITDA margin unchanged

Consolidated EBITDA margin remained flat at 9.2% year-on-year. Management said an increase in material costs limited the improvement in operating profitability. Freight expenses were also elevated, with freight costs of ₹13 crore linked to the ongoing geopolitical conflict. These costs affected the benefit that might otherwise have come from higher consolidated revenue. The company said it remains focused on operational efficiencies, cost management and profitability improvement. No EBITDA amount or net profit figure is used here because the supplied materials contain inconsistent figures on those measures. The margin commentary from management makes clear that cost pressures remained central to the quarter’s financial outcome.

Regulatory clearances support operations

Indoco Remedies reported progress in its regulatory compliance programme. Plant One at Goa cleared an audit by the UK Medicines and Healthcare products Regulatory Agency, or MHRA. Its contract research organisation facility also cleared an inspection by Brazil’s Anvisa regulator. Such clearances are relevant to pharmaceutical operations because regulatory status supports the ability to maintain and expand business with regulated markets. The company said these developments strengthened compliance. The supplied call highlights did not specify products, approvals, or revenue directly tied to either clearance. Still, the updates formed part of management’s account of operational progress during the quarter.

FY27 domestic growth guidance remains in place

In response to an analyst question, Managing Director Aditi Panandikar said the company continued to hold its high single-digit domestic growth guidance for FY27. She indicated that sales should be more predictable in H2. Management also noted that the comparison base includes about ₹65 crore of divested ophthalmic sales, based on IQVIA data. This makes the growth target more demanding because those sales are no longer part of the continuing portfolio. The managing director said the company would have likely exceeded guidance if rains had arrived as expected. That statement was presented as management’s view of the demand impact, rather than as a revised forecast. No change to the stated guidance was announced on the call.

Key Q2 FY27 figures

What the results mean for investors

The quarter establishes a higher consolidated revenue milestone for Indoco Remedies, but it does not remove near-term execution challenges. Domestic formulations declined even as certain therapy areas expanded strongly. Flat EBITDA margin shows that higher sales did not translate into year-on-year margin expansion, due to material and freight costs. The performance of Fabrix Plus, OxyPod and weather-sensitive demand conditions will remain relevant to the domestic business in the second half. At the same time, the MHRA and Anvisa inspection outcomes provide regulatory support for the company’s operating platform. Investors will also assess whether the company can deliver its retained domestic growth guidance after accounting for the divested ophthalmic sales base.

Next steps after the September quarter

The Q2 FY27 results cover the quarter ended September 30, 2026. Indoco Remedies said the audio recording of its earnings conference call was uploaded to its website on October 27. The board approved unaudited Q2 and H1 FY27 results, accompanied by an unmodified review opinion. Management’s immediate focus, based on the call, is on improving sales visibility in H2, managing input and freight costs, and maintaining operational efficiency. The next reported quarterly update will provide a clearer indication of whether domestic demand has stabilised and whether the company remains on track for its FY27 guidance. For now, the reported data show revenue growth alongside domestic and margin constraints that management will need to address.